Overview
- Revenue rose 9.6% year over year to about $19.16 billion with diluted EPS of $6.96, beating consensus estimates of $18.57 billion and $5.72.
- Adjusted EBITDA reached $3.87 billion and operating cash flow was $4.42 billion, supporting $1.29 billion of quarterly capital spending and an estimated $5 billion for 2025.
- Same-facility metrics improved, with admissions up 2.1%, equivalent admissions up 2.4%, emergency visits up 1.3%, inpatient surgeries up 1.4%, and outpatient surgeries up 1.1%, while revenue per equivalent admission increased 6.6%.
- HCA repurchased 6.514 million shares for $2.498 billion, left $3.256 billion under its current authorization, and declared a $0.72 quarterly dividend.
- The company guided 2025 revenue to $75.0–$76.5 billion, net income to $6.495–$6.715 billion, adjusted EBITDA to $15.25–$15.65 billion, and EPS to $27–$28, as shares gained about 3.8% to roughly $457; cash stood at $997 million and total debt at $44.5 billion on Sept. 30.